Abstract
Inhibition of ACAT, the enzyme which catalyses the intracellular formation of cholesteryl esters, is a very attractive target for the treatment of hypercholesterolaemia and atherosclerosis. However, in the past years many ACAT inhibitors gave disappointing results in clinical trials showing very low efficacy. In addition, their development was affected by the adrenotoxicity observed in many compounds. The discovery of two isoforms of the enzyme, namely ACAT1 and ACAT2, with different substrate specificity and different potential function, offers a precious information for planning selective inhibitors with reduced secondary effects. Today some potent, bioavailable and non adrenotoxic ACAT inhibitors are under clinical evaluation. Amongst others, a very promising compound is Avasimibe, presently in phase III clinical trials as anti-hyperlipidemic and anti-atherosclerotic agent. Finally, ACAT inhibitors have recently been proposed for the treatment of Alzheimers disease.
Keywords: cholesterol acyl-coa, cholesterol acyl transferase, atherosclerosis, anilide and urea derivatives, adrenotoxicity, alzheimer disease
Mini-Reviews in Medicinal Chemistry
Title: Selective ACAT Inhibitors as Promising Antihyperlipidemic, Antiatherosclerotic and Anti-Alzheimer Drugs
Volume: 3 Issue: 6
Author(s): M. P. Giovannoni, V. Dal Piaz, C. Vergelli and D. Barlocco
Affiliation:
Keywords: cholesterol acyl-coa, cholesterol acyl transferase, atherosclerosis, anilide and urea derivatives, adrenotoxicity, alzheimer disease
Abstract: Inhibition of ACAT, the enzyme which catalyses the intracellular formation of cholesteryl esters, is a very attractive target for the treatment of hypercholesterolaemia and atherosclerosis. However, in the past years many ACAT inhibitors gave disappointing results in clinical trials showing very low efficacy. In addition, their development was affected by the adrenotoxicity observed in many compounds. The discovery of two isoforms of the enzyme, namely ACAT1 and ACAT2, with different substrate specificity and different potential function, offers a precious information for planning selective inhibitors with reduced secondary effects. Today some potent, bioavailable and non adrenotoxic ACAT inhibitors are under clinical evaluation. Amongst others, a very promising compound is Avasimibe, presently in phase III clinical trials as anti-hyperlipidemic and anti-atherosclerotic agent. Finally, ACAT inhibitors have recently been proposed for the treatment of Alzheimers disease.
Export Options
About this article
Cite this article as:
Giovannoni P. M., Piaz Dal V., Vergelli C. and Barlocco D., Selective ACAT Inhibitors as Promising Antihyperlipidemic, Antiatherosclerotic and Anti-Alzheimer Drugs, Mini-Reviews in Medicinal Chemistry 2003; 3 (6) . https://dx.doi.org/10.2174/1389557033487890
DOI https://dx.doi.org/10.2174/1389557033487890 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cognitive Performance and Neuro-Metabolites in HIV Using 3T Magnetic Resonance Spectroscopy: A Cross-Sectional Study from India
Current HIV Research Matrix Metalloproteinases: A Therapeutic Target in Cardiovascular Disease
Current Pharmaceutical Design Current Pathophysiological Findings in Bipolar Disorder and in its Subtypes
Current Psychiatry Reviews Medication Assisted Treatment of Drug Abuse and Dependence: Global Availability and Utilization
Recent Patents on Anti-Infective Drug Discovery Validity of Alcohol Screening Instruments in General Population Gender Studies: An Analytical Review
Current Drug Abuse Reviews Tobacco Smoke Exposure, Nicotine, and the Embryologic Origins of Asthma
Current Respiratory Medicine Reviews Neuropeptides B, S and W, Obestatin/Ghrelin-Associated Peptide, and Others: Really New Feeding Regulatory Peptides?
Central Nervous System Agents in Medicinal Chemistry The Plasma Membrane: A Target and Hurdle for the Development of Anti- A? Drugs?
Current Drug Targets - CNS & Neurological Disorders The Doublecortin Gene Family and Disorders of Neuronal Structure
Central Nervous System Agents in Medicinal Chemistry A Systems Medicine Clinical Platform for Understanding and Managing Non- Communicable Diseases
Current Pharmaceutical Design Treatment of Adolescent Substance Use Disorders and Co-Occurring Internalizing Disorders: A Critical Review and Proposed Model
Current Drug Abuse Reviews Penicillium marneffei and its Pulmonary Involvements
Current Respiratory Medicine Reviews The Discovery of Novel Chemotypes of p38 Kinase Inhibitors
Current Topics in Medicinal Chemistry Pathophysiology of Sepsis in the Elderly: Clinical Impact and Therapeutic Considerations
Current Drug Targets Neuronal Acetylcholine Nicotinic Receptors as New Targets for Lung Cancer Treatment
Current Pharmaceutical Design Normobaric Hyperoxia Preconditioning Induces Changes in the Brain Lipidome
Current Neurovascular Research Metals, Toxicity and Oxidative Stress
Current Medicinal Chemistry Small Heat Shock Proteins: Recent Advances in Neuropathy
Current Neurovascular Research N-Terminal Specific Fluorescence Labeling and its Use in Local Structure Analysis of Proteins (Invited Review)
Current Chemical Biology The Cardiac Microvasculature in Hypertension, Cardiac Hypertrophy and Diastolic Heart Failure
Current Vascular Pharmacology